London, Jan 29 (ANI): Using non-infectious virus-like particles (VLP), researchers at the National Institutes of Health have developed an experimental vaccine that could successfully protect macaques and mice against chikungunya virus.

Chikungunya virus is a mosquito-borne pathogen that has infected millions of people in Africa and Asia and causes debilitating pain.

Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) developed the vaccine because there is no vaccine or treatment for chikungunya virus infection.

"Increases in global travel and trade, and possibly climate change, may be contributing to the spread of disease-carrying mosquitoes into new areas. Finding safe and effective human vaccines for chikungunya virus and other insect-borne pathogens is an important global health priority," Nature quoted NIAID Director Dr. Anthony S. Fauci as saying.

To develop the vaccine, scientists in NIAID's Vaccine Research Center (VRC) identified the proteins that give rise to chikungunya VLPs.

The VLPs mimic actual virus particles but cannot cause infection, so they can be used safely as a vaccine to elicit immune responses.

The researchers immunized rhesus macaques with the VLPs, waited 15 weeks before exposing the animals to chikungunya virus, and observed that the vaccine provided complete protection from infection.

When the group found that antibodies were responsible for immune protection, they transferred antibody-containing serum from the vaccinated macaques to mice with deficient immune systems.

The mice then were exposed to a lethal dose of chikungunya virus, but the immune serum protected them from infection.

"This virus-like particle vaccine provides a promising way to protect against an emerging infectious disease threat. This same approach could possibly extend to viruses related to chikungunya that cause fatal diseases such as encephalitis," said VRC Director Dr. Gary Nabel.

Nabel said his group plans to seek approval for clinical trials to further evaluate the safety and efficacy of the vaccine in humans.

The details about the vaccine were published in the online version of Nature Medicine. (ANI)